Showing results (521-530 of 688) with videos related to

Sort By:
Pageof 69
Lancet (London, England)|July 19, 2008
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trialPaul Emery, Ferdinand C Breedveld, Stephen Hall, et al.
ACR Open Rheumatology|January 17, 2020
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 StudyPhilip J Mease, Arthur Kavanaugh, Andreas Reimold, et al.
Rheumatology and Therapy|November 11, 2018
Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 StudiesPeter Nash, Laura C Coates, Roy Fleischmann, et al.
ACR Open Rheumatology|August 1, 2024
Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled TrialsArthur Kavanaugh, Philip Mease, Laure Gossec, et al.
Seminars in Arthritis and Rheumatism|June 11, 2020
Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 studyLaura C Coates, Peter Nash, Tore K Kvien, et al.
Drug Safety|February 2, 2021
Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III ProgramPhilip G Conaghan, Eduardo Mysler, Yoshiya Tanaka, et al.
RMD Open|November 9, 2023
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitisChristina Charles-Schoeman, Ernest Choy, Iain B McInnes, et al.
The Australasian Journal of Dermatology|July 28, 2023
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Adult patientsPeter Foley, Kurt Gebauer, John Sullivan, et al.
RMD Open|September 1, 2018
Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trialPhilip J Mease, Arthur Kavanaugh, Andreas Reimold, et al.
Critical Care Medicine|August 9, 2019
Evaluation and Predictors of Fluid Resuscitation in Patients With Severe Sepsis and Septic ShockHani I Kuttab, Joseph D Lykins, Michelle D Hughes, et al.
Pageof 69